SCHEMBL13633873

SCHEMBL13633873

Cc1nc(-c2ccc(Br)s2)oc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
HSD17B10 Q99714 2/20 0.39
ALOX12 P18054 2/20 0.39
ALOX15 P16050 1/20 0.39
KDM4E B2RXH2 6/20 0.38
LMNA P02545 4/20 0.38
POLB P06746 4/20 0.38
RXFP1 Q9HBX9 3/20 0.38
PPARG P37231 3/20 0.38
NCOA2 Q15596 3/20 0.38
ALDH1A1 P00352 6/20 0.37
RAB9A P51151 5/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
NPC1 O15118 4/20 0.37
TP53 P04637 2/20 0.37
HPGD P15428 2/20 0.37
NCOA1 Q15788 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633786 0.83 ALDH1A1 (0.46) MAPTMEN1KMT2AHSD17B10KDM4E
SCHEMBL13633902 0.80 ALDH1A1 (0.42) MAPTMEN1KMT2AHSD17B10ALOX12
SCHEMBL13633784 0.79 ALDH1A1 (0.43) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL13633783 0.76 PPARG (0.43) MAPTMEN1KMT2AKDM4EPOLB
SCHEMBL4142615 0.73 MAPT (0.36) MAPTMEN1KMT2AHSD17B10ALOX12
SCHEMBL8813501 0.69 KDM4E (0.50) MAPTMEN1KMT2AHSD17B10KDM4E
SCHEMBL5313990 0.69 ALDH1A1 (0.49) MAPTMEN1KMT2AHSD17B10KDM4E
SCHEMBL1557048 0.68 TARBP2 (0.53) MAPTMEN1KMT2AHSD17B10KDM4E
SCHEMBL13633894 0.68 IKBKB (0.55) PPARG
SCHEMBL4090912 0.68 MAPT (0.44) MAPTMEN1KMT2AHSD17B10ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 MAPT 162/4885MEN1 1197/4885KMT2A 4174/4885
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 MAPT 87/4885MEN1 2907/4885KMT2A 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.